Bharat Joshi
YOU?
Author Swipe
View article: nERdy: network analysis of endoplasmic reticulum dynamics
nERdy: network analysis of endoplasmic reticulum dynamics Open
The endoplasmic reticulum (ER) comprises smooth tubules, ribosome-studded sheets, and peripheral sheets that can present as tubular matrices. ER shaping proteins determine ER morphology, however, understanding their role in tubular matrix …
View article: Identification and characterisation of novel CAR‐T cells to target IL13Rα2 positive human glioma in vitro and in vivo
Identification and characterisation of novel CAR‐T cells to target IL13Rα2 positive human glioma in vitro and in vivo Open
Background Previously, we discovered that human solid tumours, but not normal human tissues, preferentially overexpress interleukin‐13Receptor alpha2, a high binding receptor for IL‐13. To develop novel anti‐cancer approaches, we construct…
View article: nERdy: network analysis of endoplasmic reticulum dynamics
nERdy: network analysis of endoplasmic reticulum dynamics Open
The endoplasmic reticulum (ER) comprises smooth tubules, ribosome-studded sheets, and peripheral sheets that can present as tubular matrices. ER shaping proteins determine ER morphology, however, understanding their role in tubular matrix …
View article: Caveolin‐1 promotes mitochondrial health and limits mitochondrial ROS through ROCK/AMPK regulation of basal mitophagic flux
Caveolin‐1 promotes mitochondrial health and limits mitochondrial ROS through ROCK/AMPK regulation of basal mitophagic flux Open
Caveolin‐1 (CAV1), the main structural component of caveolae, is phosphorylated at tyrosine‐14 (pCAV1), regulates signal transduction, mechanotransduction, and mitochondrial function, and plays contrasting roles in cancer progression. We r…
View article: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging Open
Background Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and neurotoxicity. Th…
View article: Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S5. Flow chart of the selection process of patients.
View article: Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S4. Hypoxia induces resistance to Abraxane in SKBR3 cells.
View article: Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S5. Flow chart of the selection process of patients.
View article: Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S7. Histology of primary breast cancer tissue.
View article: Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S1. Caspase induction in SKBR3 cells pre-incubated for 20 h in normoxia or hypoxia and treated with T-DM1 was measured using the Caspase-Glo 3/7 assay kit and the results are shown as mean luminescence (measured in relative light units [RL…
View article: Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Supplementary Table 1. Patient and tumor characteristics in relation to tumor-specific cytoplasmic intensity of CAV1
View article: Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Supplementary Table 1. Patient and tumor characteristics in relation to tumor-specific cytoplasmic intensity of CAV1
View article: Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S1. Caspase induction in SKBR3 cells pre-incubated for 20 h in normoxia or hypoxia and treated with T-DM1 was measured using the Caspase-Glo 3/7 assay kit and the results are shown as mean luminescence (measured in relative light units [RL…
View article: Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S7. Histology of primary breast cancer tissue.
View article: Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S6. CAV1 is expressed in the cytoplasm of invasive tumor cells in primary breast cancer tissue.
View article: Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
The antibody–drug conjugate trastuzumab-emtansine (T-DM1) offers an additional treatment option for patients with HER2-amplified tumors. However, primary and acquired resistance is a limiting factor in a significant subset of patients. Hyp…
View article: Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S3. Cytotoxicity of T-DM1 catabolites is not altered by hypoxia. Dose response curves showing sensitivity of normoxic or hypoxic SKBR3 and BT474 cells treated with T-DM1 catabolites, DM1 (A, D), MCC-DM1 (B, E), and LMCC-DM1 (C, F) for 72 h…
View article: Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S2. Phospho-kinase antibody array analyses of normoxia (a) or hypoxia (b) level expressed as normalized to reference standard.
View article: Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S2. Phospho-kinase antibody array analyses of normoxia (a) or hypoxia (b) level expressed as normalized to reference standard.
View article: Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S4. Hypoxia induces resistance to Abraxane in SKBR3 cells.
View article: Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S3. Cytotoxicity of T-DM1 catabolites is not altered by hypoxia. Dose response curves showing sensitivity of normoxic or hypoxic SKBR3 and BT474 cells treated with T-DM1 catabolites, DM1 (A, D), MCC-DM1 (B, E), and LMCC-DM1 (C, F) for 72 h…
View article: Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S6. CAV1 is expressed in the cytoplasm of invasive tumor cells in primary breast cancer tissue.
View article: Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
The antibody–drug conjugate trastuzumab-emtansine (T-DM1) offers an additional treatment option for patients with HER2-amplified tumors. However, primary and acquired resistance is a limiting factor in a significant subset of patients. Hyp…
View article: Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy
Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy Open
Purpose: Interleukin-13 receptor α2 (IL-13Rα2) is a tumor antigen that is overexpressed in certain human tumors. However, its significance and expression in pancreatic cancer is not known. It is also not known whether IL-13 can signal thro…
View article: Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy
Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy Open
Purpose: Interleukin-13 receptor α2 (IL-13Rα2) is a tumor antigen that is overexpressed in certain human tumors. However, its significance and expression in pancreatic cancer is not known. It is also not known whether IL-13 can signal thro…
View article: Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy
Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy Open
Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 Pseudomonas Exotoxin in Pancreatic Cancer Therapy
View article: Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy
Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 <i>Pseudomonas</i> Exotoxin in Pancreatic Cancer Therapy Open
Supplementary Data from Interleukin 13 Mediates Signal Transduction through Interleukin 13 Receptor α2 in Pancreatic Ductal Adenocarcinoma: Role of IL-13 Pseudomonas Exotoxin in Pancreatic Cancer Therapy